ECSP088236A - FORMS AND COMPOSITIONS OF PHARMACEUTICAL DOSAGES - Google Patents

FORMS AND COMPOSITIONS OF PHARMACEUTICAL DOSAGES

Info

Publication number
ECSP088236A
ECSP088236A EC2008008236A ECSP088236A ECSP088236A EC SP088236 A ECSP088236 A EC SP088236A EC 2008008236 A EC2008008236 A EC 2008008236A EC SP088236 A ECSP088236 A EC SP088236A EC SP088236 A ECSP088236 A EC SP088236A
Authority
EC
Ecuador
Prior art keywords
compositions
forms
pharmaceutical dosages
methods
formulations
Prior art date
Application number
EC2008008236A
Other languages
Spanish (es)
Inventor
Michel Bernatchez
Arwinder Nagi
Krishnendu Ghosh
Xiaohong Pan
Melissa Lin
Leonid Linberg
Eric N C Browne
Mark Lankau
Ping Cai
Sangeeta Raje
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088236A publication Critical patent/ECSP088236A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con, por ejemplo, formulaciones novedosas y métodos para el suministro de 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida, sales farmacéuticamente aceptables de éstas, compuestos estructuralmente relacionados y/o metabolitos; así como también con el uso de estas formulaciones y métodos para tratar enfermedades.The invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N - {(2R) -2- [4- (2,3-dihydro-benzo [1,4] dioxin-5- il) -piperazin-1-yl] -propyl} -N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and / or metabolites; as well as with the use of these formulations and methods to treat diseases.

EC2008008236A 2005-09-09 2008-03-04 FORMS AND COMPOSITIONS OF PHARMACEUTICAL DOSAGES ECSP088236A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71541705P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
ECSP088236A true ECSP088236A (en) 2008-04-28

Family

ID=37836444

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008236A ECSP088236A (en) 2005-09-09 2008-03-04 FORMS AND COMPOSITIONS OF PHARMACEUTICAL DOSAGES

Country Status (17)

Country Link
EP (1) EP1928863A2 (en)
JP (1) JP2009507850A (en)
KR (1) KR20080043855A (en)
CN (1) CN101258146A (en)
AR (1) AR058033A1 (en)
AU (1) AU2006287543A1 (en)
BR (1) BRPI0615771A2 (en)
CA (1) CA2620491A1 (en)
CR (1) CR9800A (en)
EC (1) ECSP088236A (en)
GT (1) GT200600403A (en)
IL (1) IL189827A0 (en)
NO (1) NO20081100L (en)
PE (1) PE20070334A1 (en)
RU (1) RU2008108216A (en)
TW (1) TW200800198A (en)
WO (1) WO2007030589A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5049450B2 (en) * 2000-09-29 2012-10-17 アボツト・ヘルスケア・プロダクツ・ベー・ブイ Sustained release pharmaceutical composition independent of ionic strength
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
BRPI0609370A2 (en) * 2005-03-01 2010-03-30 Wyeth Corp 4-cyano-n - {(2r) -2- [4- (2,3-dihydro-benzo [1,4] dioxin-5-yl) -piperazin-1-yl] -propyl} -n hydrochloride crystalline amorphous pyridin-2-yl-benzamide

Also Published As

Publication number Publication date
BRPI0615771A2 (en) 2011-05-24
IL189827A0 (en) 2008-11-03
TW200800198A (en) 2008-01-01
AR058033A1 (en) 2008-01-23
WO2007030589A2 (en) 2007-03-15
KR20080043855A (en) 2008-05-19
CN101258146A (en) 2008-09-03
PE20070334A1 (en) 2007-05-08
CA2620491A1 (en) 2007-03-15
NO20081100L (en) 2008-06-03
GT200600403A (en) 2007-09-19
EP1928863A2 (en) 2008-06-11
JP2009507850A (en) 2009-02-26
WO2007030589A3 (en) 2007-11-01
CR9800A (en) 2008-04-28
AU2006287543A1 (en) 2007-03-15
RU2008108216A (en) 2009-10-20

Similar Documents

Publication Publication Date Title
UY29562A1 (en) AMINO BENZOIL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
MXPA05012573A (en) Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors.
BRPI0408347B8 (en) pyrimidine derivatives, their use, and pharmaceutical composition and combination
CR8254A (en) [1,8] NAFTIDRIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
PA8587101A1 (en) NEW DERIVATIVES OF DIHYDROPIRIMIDO [4,5-D] PIRIMIDINONE REPLACED BY AMIINO, MANUFACTURE AND USE OF THE SAME AS PHARMACEUTICAL AGENTS
UY28766A1 (en) ADDITIONAL HETEROPOLYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER
CL2004000917A1 (en) COMPOUNDS DERIVED FROM TIAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF DISEASES MEDIATED BY DOSFATIDILNOSITOL 3-KINASE SUCH AS RESPIRATORY DISEASES, ALLERGIES, Rheumatoid Arthritis, OSTEOA
UY27740A1 (en) NEW COMPOUNDS
UY29199A1 (en) TIAZOL DERIVATIVES, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
ECSP055676A (en) HETEROCYCLIC PIPERAZINAS REPLACED FOR THE TREATMENT OF CHICHOPHRENIA
ECSP088511A (en) NEUROPEPTIDO-2 RECEIVER AGONISTS
UY30327A1 (en) NEW COMPOUNDS II
ECSP088593A (en) 5- (ARILSULFONIL) -PIRAZOLOPIPERIDINS
GT200500363A (en) 3-AMINO-PIRAZOL [3,4B] PIRIDINES WITH PROTEINTIROSINKINASE INHIBITORS, THEIR PREPARATION AND USE AS A MEDICINAL PRODUCT.
GT200500309A (en) DERIVATIVES OF SULFONILBENCILIMIDAZOL
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
UY29561A1 (en) DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
PA8568101A1 (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
ECSP066866A (en) DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS REFERENCE TO RELATED APPLICATIONS
UY29370A1 (en) DERIVATIVES OF TIAZOL, COMPOSITIONS THAT CONTAIN IT, PREPARATION PROCEDURES AND APPLICATIONS
UY27998A1 (en) HETEROCYCLIC REPLACED SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF CHICHOPHRENIA
GT200800066A (en) DERIVATIVES OF 9-CHLORINE-15-DEOXIPROSTAGLANDIN, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT.